Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078439 | 0.80 | PKM (0.51) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL2193196 | 0.77 | PKM (0.55) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL2077800 | 0.75 | PKM (0.50) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL2077595 | 0.74 | PKM (0.53) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL24369805 | 0.73 | CYP11B2 (0.33) | PKMCYP11B2 | |
| SCHEMBL28094726 | 0.73 | KDM4E (0.43) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL7823326 | 0.72 | NPC1 (0.43) | KDM4EALDH1A1KMT2AMEN1HPGD | |
| SCHEMBL4760141 | 0.72 | PKM (0.50) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL5148552 | 0.71 | SMN1; SMN2 (0.57) | PKMKDM4EALDH1A1POLBHTT | |
| SCHEMBL2075577 | 0.71 | PKM (0.49) | PKMKDM4EALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774800-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-11702419-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-07-18 | — | — | US | disclosed |
| EP-3340982-B1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-28 | — | — | US | disclosed |
| CN-111936495-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2020-11-13 | — | — | CN | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807987-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-03 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| EP-3340982-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035408-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-5302712-A | Intermediates for cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-12 | — | — | US | disclosed |
| US-5215982-A | Antibiotics | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-01 | — | — | US | disclosed |
| EP-0427248-A2 | New cephem compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807952-B2 | Compounds for treatment of immune inflammatory disorders | CFD, TFPI, CFH | PKM 4234/4885KDM4E 4269/4885ALDH1A1 3253/4885 |
| US-10807987-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | PKM 3831/4885KDM4E 1901/4885ALDH1A1 2709/4885 |
| US-20190300536-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN2B, GRIN2A, GRIN2C | PKM 3831/4885KDM4E 1901/4885ALDH1A1 2709/4885 |
| US-20180201580-A1 | COMPOUNDS FOR TREATMENT OF IMMUNE INFLAMMATORY DISORDERS | CFD, TFPI, CFH | PKM 4234/4885KDM4E 4269/4885ALDH1A1 3253/4885 |
| US-20210332053-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN2B, GRIN2A, GRIN2C | PKM 3831/4885KDM4E 1901/4885ALDH1A1 2709/4885 |
| US-11702419-B2 | Heterocyclic compound and use thereof | GRIN2B, GRIN2A, GRIN2C | PKM 3831/4885KDM4E 1901/4885ALDH1A1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.